SCHEMBL447295

SCHEMBL447295

[O]C1COc2ccccc2O1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 1/20 0.53
HTT P42858 2/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
HPGD P15428 3/20 0.50
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.49
MAPT P10636 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
MTNR1A P48039 1/20 0.49
POLB P06746 2/20 0.47
ALOX5 P09917 1/20 0.47
HTR1A P08908 1/20 0.47
ADRA2A P08913 1/20 0.47
DRD1 P21728 1/20 0.47
TBXA2R P21731 1/20 0.47
SLC6A2 P23975 1/20 0.47
ADRA1A P35348 1/20 0.47
DRD3 P35462 1/20 0.47
TSHR P16473 1/20 0.46
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL963837 0.77 NISCH (0.53) NISCHHTTSMN1; SMN2HPGDALDH1A1
SCHEMBL3568567 0.77 HPGD (0.63) NISCHHTTSMN1; SMN2HPGDALDH1A1
SCHEMBL30946854 0.75 NISCH (0.71) NISCHHTTSMN1; SMN2HPGDALDH1A1
SCHEMBL566636 0.75 HPGD (0.61) NISCHHTTSMN1; SMN2HPGDALDH1A1
SCHEMBL29437007 0.75 HPGD (0.61) NISCHHTTSMN1; SMN2HPGDALDH1A1
SCHEMBL2977327 0.75 NISCH (0.71) NISCHHTTSMN1; SMN2HPGDALDH1A1
SCHEMBL1567597 0.75 HPGD (0.61) NISCHHTTSMN1; SMN2HPGDALDH1A1
SCHEMBL1300333 0.75 HPGD (0.61) NISCHHTTSMN1; SMN2HPGDALDH1A1
SCHEMBL229498 0.75 HPGD (0.61) NISCHHTTSMN1; SMN2HPGDALDH1A1
SCHEMBL1567701 0.74 NISCH (0.50) NISCHHTTLMNAMAPTHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11179471-B2 Peptide for cytosolic delivery KYOTO UNIVERSITY (JP) 2021-11-23 US disclosed
US-20200384111-A1 MODIFIED CARBON NANOMATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER, AND PHARMACEUTICAL COMPOSITION NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2020-12-10 US disclosed
EP-3725331-A1 MODIFIED CARBON NANOMATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER, AND PHARMACEUTICAL COMPOSITION NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2020-10-21 EP disclosed
US-20200046840-A1 PEPTIDE FOR CYTOSOLIC DELIVERY KYOTO UNIVERSITY (JP) 2020-02-13 US disclosed
EP-3604520-A1 PEPTIDE FOR CYTOSOLIC DELIVERY Kyoto University (JP) 2020-02-05 EP disclosed
WO-2019078171-A1 METHOD FOR CONCENTRATING OR SEPARATING POLYMER COMPOUND 国立大学法人京都大学 2019-04-25 WO disclosed
EP-2024349-B1 COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBVIE INC (US) 2017-08-02 EP disclosed
EP-2308960-B1 CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION UNIV KYOTO (JP) 2016-01-13 EP disclosed
US-9206173-B2 Heterocyclic compounds for the treatment of stress-related conditions OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-08 US disclosed
US-20150266839-A1 CYCLIC AMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-09-24 US disclosed
US-20110086855-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBOTT LABORATORIES (US) 2011-04-14 US disclosed
EP-2308960-A1 CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION Kyoto University (JP) 2011-04-13 EP disclosed
US-7875639-B2 Compounds as cannabinoid receptor ligands and uses thereof ABBOTT LABORATORIES (US) 2011-01-25 US disclosed
WO-2010137738-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-12-02 WO disclosed
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
EP-2024349-A2 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF Abbott Laboratories (US) 2009-02-18 EP disclosed
US-20080064699-A1 Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection ABBVIE INC. 2008-03-13 US disclosed
WO-2007140439-A2 COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBOTT LABORATORIES (US) 2007-12-06 WO disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266839-A1 CYCLIC AMIDE DERIVATIVE GPR119, NR0B1, NR4A1 NISCH 2606/4885HTT 4028/4885SMN1; SMN2 3214/4885
US-20110086855-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF CNR1, CNR2, OPRL1 NISCH 1667/4885HTT 3483/4885SMN1; SMN2 2626/4885
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 NISCH 966/4885HTT 1770/4885SMN1; SMN2 3697/4885
US-20080064699-A1 Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection OPRL1, OPRK1, OPRD1 NISCH 1752/4885HTT 1356/4885SMN1; SMN2 23/4885
US-20200384111-A1 MODIFIED CARBON NANOMATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER, AND PHARMACEUTICAL COMPOSITION CHRM1, SLC67A1, NPSR1 NISCH 3301/4885HTT 4002/4885SMN1; SMN2 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.